| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | -0.083 | 0.03 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.03 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.03 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.067 | 0.03 |